Athanor Capital’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Athanor Capital’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-23,159	Closed	-$872K	–	1031
2021 Q1	$872K	Sell	23,159 -53,929	-70%	-$1.34M	0.02%	377
2020 Q4	$1.31M	Buy	77,088 +43,145	+127%	+$541K	0.03%	253
2020 Q3	$160K	Hold	33,943	–	–	0.01%	506
2020 Q2	$207K	Buy	+33,943	New	+$140K	0.01%	491
2020 Q1	–	Sell	-11,639	Closed	-$53K	–	415
2019 Q4	$53K	Buy	+11,639	New	+$46.1K	﹤0.01%	359
2019 Q3	–	Sell	-17,300	Closed	-$104K	–	244
2019 Q2	$104K	Buy	+17,300	New	+$165K	0.01%	140

Athanor Capital's FPRX Position: Q2 2021 in Review

Athanor Capital sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 23,159 shares — an estimated $872K sold.

Athanor Capital first reported a position in FPRX in Q2 2019 and held it in 6 quarters. The position peaked at $1.31M in Q4 2020. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

Athanor Capital reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
Athanor Capital sold 23,159 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $872K.
Athanor Capital first reported a position in Five Prime Therapeutics, Inc. in Q2 2019 and held it in 6 quarters.
Athanor Capital's Five Prime Therapeutics, Inc. position peaked at $1.31M in Q4 2020.
0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.

Based on Athanor Capital's 13F filing for Q2 2021, filed 16 Aug 2021.